blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3004167

EP3004167 - ONCOSTATIN M RECEPTOR ANTIGEN BINDING PROTEINS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  31.05.2019
Database last updated on 01.04.2026
FormerThe patent has been granted
Status updated on  22.06.2018
FormerGrant of patent is intended
Status updated on  23.05.2018
FormerExamination is in progress
Status updated on  23.12.2016
Most recent event   Tooltip01.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 03.08.2022  [2022/31]
Applicant(s)For all designated states
Kiniksa Pharmaceuticals, Ltd.
Clarendon House
2 Church Street
Hamilton HM 11 / BM
[2017/17]
Former [2016/15]For all designated states
Biogen MA Inc.
250 Binney Street
Cambridge, MA 02142 / US
Inventor(s)01 / ARNETT, Heather A.
3029 25th Avenue W.
Seattle, Washington 98199 / US
02 / ESCOBAR, Sabine S.
1707 E. Beaver Lake Drive SE
Sammamish, Washington 98075 / US
03 / KING, Chadwick T.
1325 Moody Avenue
North Vancouver, British Columbia V7L 3T5 / CA
04 / LIM, Ai Ching
7105 82nd Avenue SE
Mercer Island, Washington 98040 / US
05 / NARAYANAN, Saravanakumar
70 Centre Street 1C
Brookline, Massachusetts 02446 / US
06 / WEINREB, Paul H.
133 Boston Post Road
Weston, Massachusetts 02493 / US
07 / PEDERSON, Nels E.
71 Patty's Road
Mansfield, Massachusetts 02048 / US
 [2016/15]
Representative(s)Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
[2018/30]
Former [2016/15]Pohlman, Sandra M.
df-mp Dörries Frank-Molnia & Pohlman
Patentanwälte Rechtsanwälte PartG mbB
Theatinerstrasse 16
80333 München / DE
Application number, filing date14734671.230.05.2014
[2016/15]
WO2014US40360
Priority number, dateUS201361829082P30.05.2013         Original published format: US 201361829082 P
[2016/15]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2014194274
Date:04.12.2014
Language:EN
[2014/49]
Type: A2 Application without search report 
No.:EP3004167
Date:13.04.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 04.12.2014 takes the place of the publication of the European patent application.
[2016/15]
Type: B1 Patent specification 
No.:EP3004167
Date:25.07.2018
Language:EN
[2018/30]
Search report(s)International search report - published on:EP12.03.2015
ClassificationIPC:C07K16/28, C07K16/24, A61K39/395
[2018/21]
CPC:
C07K16/2866 (EP,IL,KR,US); C07K16/248 (CN,IL,KR,US); C07K16/28 (CN,IL,US);
A61K39/395 (IL,US); A61K39/39533 (IL,KR); A61P1/16 (EP,IL);
A61P1/18 (EP,IL); A61P11/00 (EP,IL); A61P17/00 (EP,IL);
A61P17/04 (EP,IL); A61P17/06 (EP,IL); A61P19/00 (EP,IL);
A61P19/02 (EP,IL); A61P25/04 (EP,IL); A61P29/00 (EP,IL);
A61P37/02 (EP,IL); A61P37/06 (EP,IL); A61P37/08 (EP,IL);
A61P43/00 (EP,IL); C07K16/244 (IL,US); C07K2317/21 (EP,CN,IL,KR,US);
C07K2317/515 (CN,IL,US); C07K2317/56 (CN,IL,US); C07K2317/565 (CN,IL,KR,US);
C07K2317/76 (EP,CN,IL,KR,US); C07K2317/92 (EP,CN,IL,KR,US) (-)
Former IPC [2016/15]C07K16/28
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/15]
Extension statesBA08.12.2015
ME08.12.2015
TitleGerman:ONCOSTATIN-M-REZEPTOR-ANTIGENBINDENDE PROTEINE[2016/15]
English:ONCOSTATIN M RECEPTOR ANTIGEN BINDING PROTEINS[2016/15]
French:PROTÉINES DE LIAISON À L'ANTIGÈNE DU RÉCEPTEUR DE L'ONCOSTATINE M[2016/15]
Entry into regional phase08.12.2015National basic fee paid 
08.12.2015Designation fee(s) paid 
08.12.2015Examination fee paid 
Examination procedure08.12.2015Examination requested  [2016/15]
09.12.2016Amendment by applicant (claims and/or description)
22.12.2016Despatch of a communication from the examining division (Time limit: M04)
24.04.2017Reply to a communication from the examining division
05.07.2017Despatch of a communication from the examining division (Time limit: M04)
12.07.2017Invitation to indicate the basis for amendments (Time limit: M01)
10.08.2017Reply to a communication from the examining division
10.08.2017Reply to an invitation to indicate the basis for amendments
12.12.2017Invitation to indicate the basis for amendments (Time limit: M01)
15.01.2018Reply to an invitation to indicate the basis for amendments
24.05.2018Communication of intention to grant the patent
15.06.2018Fee for grant paid
15.06.2018Fee for publishing/printing paid
15.06.2018Receipt of the translation of the claim(s)
Divisional application(s)EP18185359.9  / EP3456743
EP21190497.4  / EP3971212
EP23210981.9  / EP4349864
Opposition(s)26.04.2019No opposition filed within time limit [2019/27]
Fees paidRenewal fee
27.05.2016Renewal fee patent year 03
08.05.2017Renewal fee patent year 04
07.05.2018Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL25.07.2018
CY25.07.2018
EE25.07.2018
HR25.07.2018
LT25.07.2018
LV25.07.2018
MC25.07.2018
MK25.07.2018
MT25.07.2018
RS25.07.2018
SM25.07.2018
IS25.11.2018
[2022/31]
Former [2021/34]AL25.07.2018
CY25.07.2018
EE25.07.2018
HR25.07.2018
LT25.07.2018
LV25.07.2018
MC25.07.2018
MT25.07.2018
RS25.07.2018
SM25.07.2018
IS25.11.2018
Former [2021/26]AL25.07.2018
CY25.07.2018
EE25.07.2018
HR25.07.2018
LT25.07.2018
LV25.07.2018
MC25.07.2018
RS25.07.2018
SM25.07.2018
IS25.11.2018
Former [2020/07]AL25.07.2018
EE25.07.2018
HR25.07.2018
LT25.07.2018
LV25.07.2018
MC25.07.2018
RS25.07.2018
SM25.07.2018
IS25.11.2018
Former [2019/27]AL25.07.2018
EE25.07.2018
HR25.07.2018
LT25.07.2018
LV25.07.2018
RS25.07.2018
SM25.07.2018
IS25.11.2018
Former [2019/24]AL25.07.2018
EE25.07.2018
HR25.07.2018
LT25.07.2018
LV25.07.2018
RS25.07.2018
IS25.11.2018
Former [2019/12]AL25.07.2018
HR25.07.2018
LT25.07.2018
LV25.07.2018
RS25.07.2018
IS25.11.2018
Former [2019/11]HR25.07.2018
LT25.07.2018
RS25.07.2018
IS25.11.2018
Former [2019/08]LT25.07.2018
IS25.11.2018
Former [2019/07]LT25.07.2018
Cited inInternational search[I] US2006171951  (MATHER JENNIE P et al.) [I] 1-74 * The whole document, in particular the Title, Antibody LUCA38; see Examples and Deposits *
 [I]   DIVEU C ET AL: "Predominant expression of the long isoform of GP130-like (GPL) receptor is required for interleukin-31 signaling", EUROPEAN CYTOKINE NETWORK, JOHN LIBBEY EUROTEXT LTD, FR, vol. 15, no. 4, 1 January 2004 (2004-01-01), pages 291 - 302, XP002397783, ISSN: 1148-5493 [I] 1-74 * The whole document, in particular, anatagonist anti-OSMR antibody XR-M70 - see discussion §2 *
 [I]   JALAL A. JAZAYERI ET AL: "Targeting the Glycoprotein 130 Receptor Subunit to Control Pain and Inflammation", JOURNAL OF INTERFERON & CYTOKINE RESEARCH, vol. 30, no. 12, 1 December 2010 (2010-12-01), pages 865 - 873, XP055143486, ISSN: 1079-9907, DOI: 10.1089/jir.2010.0035 [I] 1-74 * The whole document, in particular Fig.1 *

DOI:   http://dx.doi.org/10.1089/jir.2010.0035
 [I]   REPOVIC PAVLE ET AL: "Oncostatin-M induction of vascular endothelial growth factor expression in astroglioma cells", ONCOGENE, NATURE PUBLISHING GROUP, GB, vol. 22, no. 50, 6 November 2003 (2003-11-06), pages 8117 - 8124, XP009125279, ISSN: 0950-9232, DOI: 10.1038/SJ.ONC.1206922 [I] 1-74 * The whole document, in particular the section 'Reagents' and p.8120, col.2, §3 *

DOI:   http://dx.doi.org/10.1038/sj.onc.1206922
 [T]   ANOMYNOUS: "SA1290581 align light chain", 29 September 2014 (2014-09-29), XP055143314, Retrieved from the Internet [retrieved on 20140929] [T] * the whole document *
 [T]   ANOMYNOUS: "SA1290581 Heavy chain align", 29 September 2014 (2014-09-29), XP055143316, Retrieved from the Internet [retrieved on 20140929] [T] * the whole document *
 [T]   ANOMYNOUS: "SA1290581 identity of SEQ ID NO:29", 29 September 2014 (2014-09-29), XP055143370, Retrieved from the Internet [retrieved on 20140929] [T]
 [A]   RUDIKOFF S ET AL: "Single amino acid substitution altering antigen-binding specificity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, vol. 79, 1 March 1982 (1982-03-01), pages 1979 - 1983, XP007901436, ISSN: 0027-8424, DOI: 10.1073/PNAS.79.6.1979 [A] 1-74 * the whole document *

DOI:   http://dx.doi.org/10.1073/pnas.79.6.1979
 [A]   PANKA D J ET AL: "VARIABLE REGION FRAMEWORK DIFFERENCES RESULT IN DECREASED OR INCREASED AFFINITY OF VARIANT ANTI-DIGOXIN ANTIBODIES", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, vol. 85, no. 9, 1 May 1988 (1988-05-01), pages 3080 - 3084, XP000611718, ISSN: 0027-8424, DOI: 10.1073/PNAS.85.9.3080 [A] 1-74 * the whole document *

DOI:   http://dx.doi.org/10.1073/pnas.85.9.3080
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.